NEW YORK (360Dx) – Diazyme Laboratories today said that the US Food and Drug Administration has provided 510(k) clearance to the company to market its procalcitonin assay for diagnosing sepsis.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.